These pathway activations may allow for the progression of breast cancer [57–59], and this has been directly suggested by Vivacqua et al. [44] with overexpression of GPR30 in the development of aggressive phenotypes in estrogen-dependent breast cancers. The gene discussed is GPER1; the disease is breast cancer.